Emerging Pharmaceutical Markets Globally

Emerging Pharmaceutical Markets Globally

The report ``Emerging Pharmaceutical Markets Globally`` provides an exhaustive overview of the pharmaceutical markets in the E7 countries (Brazil, Russia, India, China, Mexico, Turkey and Indonesia). This Report provides a detailed account of the factors that are redefining the structure and composition of the global pharmaceutical market and causing a shift in growth from the mature markets to the emerging ones.

Statistics and analysis regarding market size, growth, structure, exports and imports, therapy mix, share of branded and generic drugs, healthcare financing, market share of key players, as well as key drivers and restraints and trends in technology development have been thoroughly analyzed in this report.

The report also envisages the fact that the markets in the E7 have huge differences as compared to the developed markets in terms of traditional therapies, intellectual property, health insurance scenario and so forth. Thus, it provides valuable information to pharmaceutical companies and investors looking to foray into these markets and help them devise strategies according to the E7 markets.

Key Findings

• The E7 Pharmaceutical markets are expected to grow at a CAGR 11.5% between 2007 and 2012 reaching revenues worth nearly US$ 116 Billion. In contrast the G7 Pharmaceutical markets are projected to grow at CAGR 4.95% between the same periods.
  
  
• The pharmaceutical markets in India, China and Turkey are expected to grow the fastest among all the E7 nations.
  
  
• The E7 nations are expected to account for nearly half of the 6.99 Billion global populations in 2012.
  
  
• Cardiovascular, cancer and other chronic diseases have taken over communicable diseases as the biggest killers in these nations.
  
  
• The Pharmaceutical market in most of these regions is still dominated by acute therapies, but with the growth rate of chronic therapies far exceeding that of acute therapies, the therapy mix of the market will be much different in the next five years from what it is today.
  
  
• The markets in India, China, Russia and Indonesia are dominated by generics. Generics however have a lower penetration in Brazil, Mexico and Turkey.
  
  
• Inadequate protection of intellectual property and large-scale prevalence of counterfeit drugs remains a major challenge faced by the pharmaceutical industry in these regions.

Key Issues & Facts Analyzed

• Evaluation of past, current and future market trends.
  
  
• Evaluation of the market by segment.
  
  
• Discussion about the major drivers of the pharmaceutical market.
  
  
• Analysis of the opportunities created by the market.
  
  
• Analysis of the major challenges faced by the market.
  
  
• Competitive landscape of the market.

Key Players Analyzed

This section provides the overview, key facts and financial information of prominent players in the E7 pharmaceutical market like GlaxoSmithKline, Sanofi-Aventis, Pfizer Inc., Novartis, and AstraZeneca.

Research Methodology Used

Information Sources
Information has been sourced from books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.

Analysis Methods
The analysis methods include ratio analysis, historical trend analysis, and linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis. 
 

1. Analyst View

2. Global Pharmaceutical Market

2.1 Market Size

2.2 Mature Markets - G7 Countries

2.3 Emerging Markets - E7 Countries

2.4 E7 Countries to Grow Strongly

3. Why E7 Pharmaceutical Market?

3.1 Economic Growth

3.2 Income Level

3.3 Population Base

3.4 Prevalence of Lifestyle-related Diseases

3.5 Medical & Distribution Infrastructure

3.6 Health Insurance

4. Industry Performance

4.1 Brazil (Past, Present & Future Scenario)

4.1.1 Macroeconomic Indicators

4.1.2 Population Profile

4.1.3 Disease Profile

4.1.4 Healthcare Spending & Financing

4.1.5 Pharmaceutical Market

4.1.6 Import & Export

4.1.7 Generic Drugs

4.1.8 Therapy Areas

4.1.9 Key Players

4.2 Russia (Past, Present & Future Scenario)

4.2.1 Macroeconomic Indicators

4.2.2 Population Profile

4.2.3 Disease Profile

4.2.4 Healthcare Spending & Financing

4.2.5 Pharmaceutical Market

4.2.6 Import

4.2.7 Branded & Generic Drugs

4.2.8 Therapy Areas

4.2.9 Key Players

4.3 India (Past, Present & Future Scenario)

4.3.1 Macroeconomic Indicators

4.3.2 Population Profile

4.3.3 Disease Profile

4.3.4 Healthcare Spending & Financing

4.3.5 Pharmaceutical Market

4.3.6 Import & Export

4.3.7 Branded & Generic Drugs

4.3.8 Therapy Areas

4.3.9 Key Players

4.4 China (Past, Present & Future Scenario)

4.4.1 Macroeconomic Indicators

4.4.2 Population Profile

4.4.3 Disease Profile

4.4.4 Healthcare Spending & Financing

4.4.5 Pharmaceutical Market

4.4.6 Import & Export

4.4.7 Branded & Generic Drugs

4.4.8 Therapy Areas

4.4.9 Key Players

4.5 Turkey (Past, Present & Future Scenario)

4.5.1 Macroeconomic Indicators

4.5.2 Population Profile

4.5.3 Disease Profile

4.5.4 Healthcare Spending & Financing

4.5.5 Pharmaceutical Market

4.5.6 Import & Export

4.5.7 Branded & Generic Drugs

4.5.8 Therapy Areas

4.5.9 Key Players

4.6 Mexico (Past, Present & Future Scenario)

4.6.1 Macroeconomic Indicators

4.6.2 Population Profile

4.6.3 Disease Profile

4.6.4 Healthcare Spending & Financing

4.6.5 Pharmaceutical Market

4.6.6 Import & Export

4.6.7 Branded & Generic Drugs

4.6.8 Therapy Areas

4.6.9 Key Players

4.7 Indonesia (Past, Present & Future Scenario)

4.7.1 Macroeconomic Indicators

4.7.2 Population Profile

4.7.3 Disease Profile

4.7.4 Healthcare Spending & Financing

4.7.5 Pharmaceutical Market

4.7.6 Import & Export

4.7.7 Branded & Generic Drugs

4.7.8 Key Players

5. Opportunities

5.1 Chronic Diseases

5.2 Pharma Outsourcing Market

5.3 Vaccine Market

5.4 Medical Devices Market

6. Restraining Forces

6.1 Counterfeit Drugs

6.2 Patent Protection

6.3 Traditional Medicines

7. Key Players

7.1 GlaxoSmithKline

7.2 Sanofi-Aventis

7.3 Pfizer Inc.

7.4 Novartis

7.5 AstraZeneca

List of Figures:

Figure 2-1: Global - Pharmaceutical Market* (in Billion US$), 2001-2007E

Figure 2-2: Global - Forecast for Pharmaceutical Market* (in Billion US$), 2008-2012

Figure 2-3: G7 Countries - Pharmaceutical Markets (in Billion US$), 2007E

Figure 2-4: G7 Countries - Forecast for Pharmaceutical Markets (in Billion US$), 2012

Figure 2-5: G7 Countries - CAGR Growth of Pharmaceutical Markets (%), 2007-2012

Figure 2-6: E7 Countries - Pharmaceutical Markets (in Billion US$), 2007E

Figure 2-7: E7 Countries - Forecast for Pharmaceutical Markets (in Billion US$), 2012

Figure 2-8: E7 Countries - CAGR Growth of Pharmaceutical Markets (%), 2007-2012

Figure 2-9: Global - Pharmaceutical Market by E7 & G7 Countries (%), 2007E & 2012F

Figure 2-10: Global - Share of E7 & G7 Countries in Pharmaceutical Market Growth (%), 2007-2012

Figure 3-1: G7 Countries - Real GDP (in Trillion US$), 2004 & 2012F

Figure 3-2: E7 Countries - Real GDP (in Trillion US$), 2004 & 2012F

Figure 3-3: Global - Share of E7 & G7 Countries in Population (%), 2007E & 2012F

Figure 3-4: Relative Per Capita Spending on Drugs by Age Group

Figure 3-5: India - Prevalence of various Lifestyle-related Diseases (in Million), 2005 & 2015F

Figure 4-1: Brazil - Nominal GDP (in Billion US$), 2005-2012F

Figure 4-2: Brazil - Consumer Price Index (%), 2005-2012F

Figure 4-3: Brazil - Currency Exchange Rate (From US$ to BRL), 2005-2012F

Figure 4-4: Brazil - Foreign Direct Investment (in Billion US$), 2004-2007

Figure 4-5: Brazil - Population (in Million), 2005-2012F

Figure 4-6: Brazil - Breakup of Population by Age Group (%), 2005-2012F

Figure 4-7: Brazil - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F

Figure 4-8: Brazil - Number of Deaths due to Leading Causes (in ‘000), 2005

Figure 4-9: Brazil - Breakup of Deaths by various Causes (%), 2005-2012F

Figure 4-10: Brazil - Per Head Healthcare Spending (in US$), 2004-2012F

Figure 4-11: Brazil - Breakup of Healthcare Payment by Source (%), 2006

Figure 4-12: Brazil - Pharmaceutical Market (in Billion BRL), 2001, 2002 & 2004-2007E

Figure 4-13: Brazil - Pharmaceutical Market (in Billion Units), 2004-2007E

Figure 4-14: Brazil - Forecast for Pharmaceutical Market (in Billion BRL), 2008-2012

Figure 4-15: Brazil - Pharmaceutical Imports (in Billion US$), 2004-2007E

Figure 4-16: Brazil - Pharmaceutical Exports (in Million US$), 2004-2007E

Figure 4-17: Brazil - Generic Drugs (in Million US$), 2004-2007E

Figure 4-18: Brazil - Forecast for Generic Drugs (in Million US$), 2008-2012

Figure 4-19: Brazil - Share of Generic Drugs in Pharmaceutical Market* (%), 2007E & 2012F

Figure 4-20: Brazil - Breakup of Pharmaceutical Market by Segment (%), Dec 2007

Figure 4-21: Russia - Nominal GDP (in Billion US$), 2005-2012F

Figure 4-22: Russia - Consumer Price Index (%), 2005-2012F

Figure 4-23: Russia - Currency Exchange Rate (From US$ to RUB), 2005-2012F

Figure 4-24: Russia - Foreign Direct Investment (in Billion US$), 2004-2007

Figure 4-25: Russia - Population (in Million), 2005-2012F

Figure 4-26: Russia - Breakup of Population by Age Group (%), 2005-2012F

Figure 4-27: Russia - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F

Figure 4-28: Russia - Number of Deaths due to Leading Causes (in '000), 2005

Figure 4-29: Russia - Breakup of Deaths by various Causes (%), 2005-2012F

Figure 4-30: Russia - Per Head Healthcare Spending (in US$), 2004-2012F

Figure 4-31: Russia - Breakup of Healthcare Payment by Source (%), 2005

Figure 4-32: Russia - Domestic Pharmaceutical Market (in Billion US$), 2005-2007E

Figure 4-33: Russia - Domestic Pharmaceutical Market by Segment (in Billion US$), 2005-2007E

Figure 4-34: Russia - Forecast for Domestic Pharmaceutical Market (in Billion US$), 2008-2012

Figure 4-35: Russia - Pharmaceutical Imports (in Billion US$), 2005-2007E

Figure 4-36: Russia - Breakup of Pharmaceutical Market* by Branded & Generic Drugs (%), 2005

Figure 4-37: India - Nominal GDP (in Billion US$), 2005-2012F

Figure 4-38: India - Consumer Price Index (%), 2005-2012F

Figure 4-39: India - Currency Exchange Rate (From US$ to INR), 2005-2012F

Figure 4-40: India - Foreign Direct Investment (in Billion US$), 2002-03 to 2006-07

Figure 4-41: India - Foreign Direct Investment in Pharmaceutical Market (in Million US$), 2003-04 to 2006-07

Figure 4-42: India - Population (in Million), 2005-2012F

Figure 4-43: India - Breakup of Population by Age Group (%), 2005-2012F

Figure 4-44: India - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F

Figure 4-45: India - Number of Deaths due to Leading Causes (in '000), 2005

Figure 4-46: India - Breakup of Deaths by various Causes (%), 2005-2012F

Figure 4-47: India - Per Head Healthcare Spending (in US$), 2005-2012F

Figure 4-48: India - Breakup of Healthcare Payment by Source (%), 2006

Figure 4-49: India - Domestic Pharmaceutical Market* (in Billion INR), 2001-02 to 2006-07

Figure 4-50: India - Forecast for Domestic Pharmaceutical Market* (in Billion INR), 2007-08 to 2011-12

Figure 4-51: India - Pharmaceutical Imports (in Billion INR), 2000-01 to 2006-07E

Figure 4-52: India - Pharmaceutical Exports (in Billion INR), 2005-06 to 2011-12F

Figure 4-53: India - Breakup of Domestic Pharmaceutical Market by Segment (%), 2004 & 2010F

Figure 4-54: India - Share of Top Players in Pharmaceutical Market (%), 2006

Figure 4-55: China - Nominal GDP (in Billion US$), 2005-2012F

Figure 4-56: China - Consumer Price Index (%), 2005-2012F

Figure 4-57: China - Currency Exchange Rate (From US$ to CNY), 2005-2012F

Figure 4-58: China - Foreign Direct Investment (in Billion US$), 2004-2007

Figure 4-59: China - Population (in Million), 2005-2012F

Figure 4-60: China - Breakup of Population by Age Group (%), 2005-2012F

Figure 4-61: China - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F

Figure 4-62: China - Number of Deaths due to Leading Causes (in '000), 2005

Figure 4-63: China - Breakup of Deaths by various Causes (%), 2005-2012F

Figure 4-64: China - Per Head Healthcare Spending (in US$), 2004-2012F

Figure 4-65: China - Breakup of Healthcare Payment by Source (%), 2006

Figure 4-66: China - Domestic Pharmaceutical Market (in Billion US$), 1996, 2000 & 2005-2007E

Figure 4-67: China - TCM Market (in Billion CNY), 2005-2007E

Figure 4-68: China - Pharmaceutical Purchase by Source (%), 2003

Figure 4-69: China - Forecast for Domestic Pharmaceutical Market (in Billion US$), 2008-2012

Figure 4-70: China - Medicine & Health Product Imports (in Billion US$), 2005-2007E

Figure 4-71: China - Breakup of Medicine & Health Product Imports by Type (%), 2006

Figure 4-72: China - Medicine & Health Product Exports (in Billion US$), 2005-2007E

Figure 4-73: China - Breakup of Medicine & Health Product Exports by Type (%), 2006

Figure 4-74: China - Breakup of Domestic Pharmaceutical Market by Segment (%), 2003

Figure 4-75: Turkey - Nominal GDP (in Billion US$), 2005-2012F

Figure 4-76: Turkey - Consumer Price Index (%), 2005-2012F

Figure 4-77: Turkey - Currency Exchange Rate (From US$ to TRY), 2005-2012F

Figure 4-78: Turkey - Foreign Direct Investment (in Billion US$), 2004-2007

Figure 4-79: Turkey - Population (in Million), 2005*-2012F

Figure 4-80: Turkey - Breakup of Population by Age Group (%), 2005*-2012F

Figure 4-81: Turkey - Population in the Age Group of 65 Years & Above (in Million), 2005*-2012F

Figure 4-82: Turkey - Number of Deaths due to Leading Causes (in '000), 2005

Figure 4-83: Turkey - Breakup of Deaths by various Causes (%), 2005-2012F

Figure 4-84: Turkey - Per Head Healthcare Spending (in US$), 2004-2012F

Figure 4-85: Turkey - Breakup of Healthcare Payment by Source (%), 2005

Figure 4-86: Turkey - Domestic Pharmaceutical Market (in Billion US$), 2005-2007E

Figure 4-87: Turkey - Domestic Pharmaceutical Market (in Million Boxes), 2002-2007E

Figure 4-88: Turkey - Forecast for Domestic Pharmaceutical Market (in Billion US$), 2008-2012

Figure 4-89: Turkey - Breakup of Pharmaceutical Market* by Imported & Locally-produced Drugs (%), 2004-2007E

Figure 4-90: Turkey - Pharmaceutical Exports (in Million US$), 2004-2007E

Figure 4-91: Turkey - Breakup of Pharmaceutical Market Sales Value* by Branded & Generic Drugs (%), 2004- 2007E

Figure 4-92: Turkey - Breakup of Pharmaceutical Market Sales Volume* by Branded & Generic Drugs (%), 2004-2007E

Figure 4-93: Mexico - Nominal GDP (in Billion US$), 2005-2012F

Figure 4-94: Mexico - Consumer Price Index (%), 2005-2012F

Figure 4-95: Mexico - Currency Exchange Rates (From US$ to MXN), 2005-2012F

Figure 4-96: Mexico - Foreign Direct Investment (in Billion US$), 2004-2007

Figure 4-97: Mexico - Population (in Million), 2005-2012F

Figure 4-98: Mexico - Breakup of Population by Age Group (%), 2005-2012F

Figure 4-99: Mexico - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F

Figure 4-100: Mexico - Number of Deaths due to Leading Causes (in '000), 2005

Figure 4-101: Mexico - Breakup of Deaths by various Causes (%), 2005-2012F

Figure 4-102: Mexico - Per Head Healthcare Spending (in US$), 2004-2012F

Figure 4-103: Mexico - Breakup of Healthcare Payment by Source (%), 2004

Figure 4-104: Mexico - Domestic Pharmaceutical Market (in Billion Pesos), 2004-2007E

Figure 4-105: Mexico - Forecast for Domestic Pharmaceutical Market (in Billion Pesos), 2008-2012

Figure 4-106: Mexico - Pharmaceutical Imports (in Billion US$), 2003 & 2007E

Figure 4-107: Mexico - Pharmaceutical Exports (in Billion US$), 2003, 2006 & 2007E

Figure 4-108: Mexico - Breakup of Pharmaceutical Market* by Branded & Generic Drugs (&), 2004

Figure 4-109: Mexico - Generic Market (in Billion MXN), 2003 & 2004

Figure 4-110: Mexico - Share of Top Players in Pharmaceutical Market (%), 2007

Figure 4-111: Indonesia - Nominal GDP (in Billion US$), 2005-2012F

Figure 4-112: Indonesia - Consumer Price Index (%), 2005-2012F

Figure 4-113: Indonesia - Currency Exchange Rates (From US$ to Rp), 2005-2012F

Figure 4-114: Indonesia - Foreign Direct Investment (in Billion US$), 2005-2007

Figure 4-115: Indonesia - Population (in Million), 2005-2012F

Figure 4-116: Indonesia - Breakup of Population by Age Group (%), 2005-2012F

Figure 4-117: Indonesia - Population in the Age Group of 65 Years & Above (in Million), 2005-2012F

Figure 4-118: Indonesia - Number of Deaths due to Leading Causes (in '000), 2005

Figure 4-119: Indonesia - Breakup of Deaths by various Causes (%), 2005-2012F

Figure 4-120: Indonesia - Per Head Healthcare Spending (in US$), 2004-2012F

Figure 4-121: Indonesia - Breakup of Healthcare Payment by Source (%), 2003

Figure 4-122: Indonesia - Domestic Pharmaceutical Market (in Billion Rp), 2000-2007E

Figure 4-123: Indonesia - Prescription & OTC Drugs Market (in Billion Rp), 2000-2007E

Figure 4-124: Indonesia - Forecast for Domestic Pharmaceutical Market (in Billion Rp), 2008-2012

Figure 4-125: Indonesia - Pharmaceutical Exports (in Billion Rp) 2001-2005

Figure 4-126: Indonesia - Pharmaceutical Imports (in Billion Rp) 2001-2005

Figure 4-127: Indonesia - Breakup of Pharmaceutical Market by Branded & Generic Drugs (%), 2005

Figure 4-128: Indonesia - Share of Top Players in Prescription Pharmaceutical Market (%), 2005

Figure 4-129: Indonesia - Share of Top Players in OTC Pharmaceutical Market (%), 2005

Figure 5-1: Global - Pharma Outsourcing Market by Segment (%), 2006

Figure 5-2: BRIC Countries - Medical Device Market (in Million US$), 2006